Development and validation of RP-HPLC method for the estimation of Erlotinib in pharmaceutical formulation

Development and validation of RP-HPLC method for the estimation of Erlotinib in pharmaceutical formulation

In this study, a simple, precise and accurate reverse phase high performance liquid chromatography was developed for the estimation of Erlotinib in bulk and pharmaceutical dosage forms. A reverse phase Merck C18 column (250cm×4.6mm×5μm) with mobile phase consisting of potassium dihydrogen orthophosp...

Full description

Saved in:
Bibliographic Details
Published in:Arabian journal of chemistry Vol. 10; no. S1; pp. S1138 - S1144
Main Authors: Latha, S.T., Ananda Thangadurai, S., Jambulingam, M., Sereya, K., Kamalakannan, D., Anilkumar, M.
Format: Journal Article
Language:English
Published: Elsevier B.V 01-02-2017
Elsevier
Subjects:
Erlotinib
Reverse phase-HPLC method
UV detector
Erlotinib
UV detector
Reverse phase-HPLC method
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study, a simple, precise and accurate reverse phase high performance liquid chromatography was developed for the estimation of Erlotinib in bulk and pharmaceutical dosage forms. A reverse phase Merck C18 column (250cm×4.6mm×5μm) with mobile phase consisting of potassium dihydrogen orthophosphate and acetonitrile (70:30 V/V) having pH 5.0 was adjusted with orthophosphoric acid was used. The flow rate was 0.8mLmin−1 and the effluents were monitored at 246nm. The retention time was found to be 4.54min. The linearity of the drug was obtained in the range of 10–60μgmL−1. The results of analysis have been validated according to ICH guideline requirements for registration of human use.
ISSN:1878-5352
1878-5379
DOI:10.1016/j.arabjc.2013.02.006